Pacitti David 4

What Happened David Pacitti, Chief Executive Officer of Avanos Medical (AVNS), was granted awards on March 13, 2026 totaling 340,695 units: 101,341 time‑based restricted share units (TRSUs) and 239,354 performance/derivative RSUs. Both awards were reported at $0 acquisition price (compensation awards), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-03-13; Form 4 filed 2026-03-17 (filed within required two business days).
• Grant amounts and price: 101,341 TRSUs @ $0; 239,354 derivative RSUs @ $0. Total units = 340,695.
• Vesting: TRSUs vest 1/3 on 3/13/2027, 1/3 on 3/13/2028, 1/3 on 3/13/2029 (F1). The other award vests 30% on 3/13/2027, 30% on 3/13/2028 and 40% on 3/13/2029 (F2).
• Plan/source: Awards granted under the Issuer's 2021 Long Term Incentive Plan (per footnotes). Each TRSU is the economic equivalent of one share.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Report appears timely (filed within the regulatory window).

Context These grants are compensation awards that convert to shares only as they vest (time‑ and performance‑based vesting schedules apply). They are not immediate purchases or sales and therefore do not signal an immediate personal market stake change like an open‑market buy/sell would. Such awards are common for aligning executive incentives with long‑term shareholder outcomes.